Vitamin D for Health & Longevity - Quick Reference Sheet

Vitamin D for Health & Longevity

Created on 07/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Vitamin D acts like a hormone controlling calcium, bone, and immune function. Its clearest value is correcting genuine deficiency and preventing the resulting bone disease. Steady daily use may lower cancer deaths, new autoimmune conditions, and infections in deficient people. Benefit concentrates in those who start low; excess intake risks high calcium and kidney stones. (Full Review)

Protocol

Maintenance Dose
1,000–2,000 IU/day
Vitamin D3; 1.5–3× higher for obesity or malabsorption
Form
Vitamin D3 (cholecalciferol)
Preferred over D2; absorbed best with largest fat-containing meal
Schedule
Daily or weekly
Large monthly or annual boluses discouraged
Time to effect
Deficiency Correction
Weeks to months
Established deficiency resolves with repletion
Blood Level
8–12 weeks
25(OH)D reaches steady state
Bone & PTH
Months
Downstream bone and parathyroid effects

Benefits

Contraindications
  • Hypercalcemia
  • Granulomatous disease (active sarcoidosis, tuberculosis)
  • Primary hyperparathyroidism
  • Certain lymphomas
  • Known CYP24A1 mutations
  • Documented hypervitaminosis D
  • Advanced kidney disease (eGFR <30)
  • Recurrent calcium stone-formers
Key Interactions
  • Thiazide diuretics (hydrochlorothiazide, chlorthalidone)
  • Enzyme-inducing anticonvulsants (phenytoin, phenobarbital, carbamazepine), rifampin
  • Glucocorticoids (prednisone)
  • Digoxin
  • Ketoconazole
  • Fat-blockers, bile-acid sequestrants (orlistat, cholestyramine, colestipol)
  • High-dose calcium
  • High-dose vitamin A
  • Magnesium (required cofactor)

Risk & Side Effects

  • High: Hypercalcemia and hypercalciuria
  • Medium: Kidney stones; adverse effects of high-dose bolus regimens
  • Low: Vitamin D toxicity from mislabeled or overdosed products
  • Speculative: Possible U-shaped mortality relationship at very high levels; vascular and soft-tissue calcification with concurrent high calcium

Monitoring

Marker Target Why
25-hydroxyvitamin D [25(OH)D] 40–60 ng/mL Primary marker of vitamin D status
Serum calcium 9.0–10.0 mg/dL Detects hypercalcemia from over-supplementation
Intact parathyroid hormone (PTH) 15–40 pg/mL Signals functional vitamin D insufficiency
24-hour urine calcium <250–300 mg/day Detects hypercalciuria before stones form
Magnesium (RBC) 5.0–6.5 mg/dL Required cofactor for vitamin D activation

Cadence: Recheck 25(OH)D at 8–12 weeks after starting or changing dose, then every 6–12 months once stable; check serum calcium periodically at higher doses

Qualitative Assessment

  • Energy levels and reduced daytime fatigue
  • Mood and seasonal (winter) well-being
  • Frequency and severity of respiratory infections
  • Bone and muscle aches or unexplained weakness
  • Sleep quality